UCB, announced key findings from the first retrospective patient cohort study in Denmark to observe the characteristics of patients selected for romosozumab treatment in routine clinical practice.
Mylan N.V. and Biocon Ltd. announced submission of Mylan's biologics license application (BLA) for MYL 1401O, a proposed biosimilar trastuzumab,...
Mylan N.V. and Biocon Ltd. announced that the FDA has approved Mylan’s Fulphila (pegfilgrastim-jmbd), a biosimilar to Neulasta (pegfilgrastim), co-developed...